23 January 2018: ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announced on 5 January 2018 details of a proposed of the existing ordinary share capital of the Company. The Board is pleased to announce that at today’s General Meeting of the Company, Shareholders approved all of the Resolutions set out in the Circular.